POSSIBILITIES OF FORECASTING EARLY PREECLAMPSIA IN 11-13 WEEK OF GESTATION
https://doi.org/10.15372/SSMJ20190211
Abstract
The purpose of the study was to study the levels of placental growth factor (PlGF) and soluble receptor-1 vascular endothelial growth factor (sVEGF-R1) in the mother’s serum during normal pregnancy and pre-eclampsia developed before 34 weeks of pregnancy in the period 11–13 weeks. Material and methods. In a prospective study, 95 patients were selected on the basis of risk factors for the development of pre-eclampsia in the first prenatal screen and further examined blood for PlGF and sVEGF-R1. According to the results of the course of pregnancy, the patients were divided into 4 groups: the first group – preeclampsia developed before the 34th week of pregnancy, the 2nd group – uncomplicated pregnancy, the 3rd group – pregnancy proceeding with fetoplacental insufficiency, the 4th group – pregnancy ending in preterm labor. Results and discussion. In women with preeclampsia that developed before the 34th week of gestation, the medians of sVEGF and PlGF were 2275 and 64.5 pg/ml, respectively, in pregnancy with placental insufficiency – 648.9 and 31.5 pg/ml, in pregnancy ending in preterm labor – 102.5 and 20 pg/ml, in uncomplicated pregnancy – 1170.0 and 34,5 pg/ml. The results can be used in the screening of the first trimester of pregnancy to predict various pathological conditions of pregnancy.
About the Authors
L. D. Belotserkovtseva
Medical Institute of Surgut State University
Russian Federation
Russian Federation
doctor of medical sciences, professor, head of the department of obstetrics, gynecology and perinatology
628412, Surgut, Lenin av., 1
L. V. Kovalenko
Medical Institute of Surgut State University
Russian Federation
Russian Federation
doctor of medical sciences, professor, head of the department of general pathology and pathophysiology
628412, Surgut, Lenin av., 1
D. P. Telitsyn
Medical Institute of Surgut State University
Russian Federation
Russian Federation
postgraduate student of the department of obstetrics and gynecology
628412, Surgut, Lenin av., 1
References
1. Белоцерковцева Л.Д., Коваленко Л.В., Телицын Д.П. Ретроспективный анализ ранних преэклампсий в Сургутском клиническом перинатальном центре // Вестн. СурГУ. Мед. 2017. (4). 17–21.
2. Филлипов О.С., Гусева Е.В., Сидорова И.С., Никитина Н.А. Материнская смертность в Российской Федерации: анализ официальных данных и результаты конфиденциального аудита в 2013 году. Методическое письмо Министерства здравоохранения Российской Федерации № 15-4/10/2-7509 от
3. 10.2014. 91 с.
4. Филиппов О.С., Гусева Е.В., Малышкина А.И., Михайлов А.В., Линде В.А., Зубенко Н.В., Фаткуллин И.Ф., Башмакова Н.В., Артымук Н.В., Пестрикова Т.Ю. Материнская смертность в Российской Федерации в 2015 году. Методическое письмо Министерства здравоохранения Российской Федерации № 15-4/10/2-6810 от 28.10.2016. 85 с.
5. Щербаков В.И., Поздняков И.М., Ширинская А.В., Волков М.В. Уровень интерлейкина-6, растворимых рецепторов интерлейкина-6 и сосудисто-эндотелиального фактора роста при срочных родах, угрозе преждевременных родов и преэклампсии // Акушерство и гинекология. 2017. (3). 50–54.
6. Carmeliet P. Angiogenesis in health and disease // Nat. Med. 2003. 9. 653–660.
7. Fong G.H., Rossant J., Gertsentein M., Breitman M.L. Role of the Flt-1 tyrosine kinase in regulating the assembly of vascular endothelium // Nature. 1995. 376. 66–70.
8. Hiratsuka S., Minova O., Kuno J., Noda T., Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice // Proc. Natl. Acad. Sci. USA. 1998. 95. 9349–9354.
9. Kvehaugen A.S., Dechend R., Ramstad H.B., Troisi R., Fugelseth D., Staff A.C. Endothelial function and circulating biomarkers are disturbed in women and children after preeclampsia // Hypertension. 2011. 58. (1). 63–69.
10. Ogge G., Chaiworapongsa T., Romero R., Hussein Y., Kusanovic J.P., Yeo L., Kim C.J., Hassan S.S. Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia // J. Perinat. Med. 2011. 39. (6). 641–652.
11. Redman C.W., Sargent I.L., Staft A.C. IFPA Senior award lecture: making sense of pre-eclampsia – two placental causes of preeclampsia // Placenta. 2014. 35. s20–s25.
12. Shibuya M. Structure and function of VEGF/ VEGF-receptor system involved in angiogenesis // Cell Struct. Funct. 2001. 26. 25–35
13. Staff A.C. Circulating predictive biomarkers in preeclampsia // Pregnancy Hypertens. 2011. 1. (1). 28–42.
14. Stevens W., Shih T., Incerti D., Ton T.G.N., Lee H.C., Peneva D., Macones G.A., Sibai B.M., Jena A.B. Short-term costs of preeclampsia to the United States health care system // Am. J. Obstet. Gynecol. 2017. 217. (3). 237–248.
15. Tsatsaris V., Muller F., Maillard F., Delattre M., Guibourdenche J., Dreux S., Winer N., Brion D.E., Goffinet F. OS039. Early prediction of preeclampsia with maternal parameters, SVEGF-R1, PLGF, Inhibin-A and PAPP-A in general population: Results from the MSPE study // Pregnancy Hypertens. 2. (3). 197–198.
Review
For citations:
Belotserkovtseva L.D., Kovalenko L.V., Telitsyn D.P. POSSIBILITIES OF FORECASTING EARLY PREECLAMPSIA IN 11-13 WEEK OF GESTATION. Сибирский научный медицинский журнал. 2019;39(2):81-85. (In Russ.) https://doi.org/10.15372/SSMJ20190211
Views:
224
Email this article 